|

Clinical Trials in Rhode Island

274 recruiting studies across 9 cities, spanning 15 conditions.

Browse by Condition

All Trials in Rhode Island

Phase
Trial Phase Location
Implementing Low-Barrier HCV Treatment in a Jail SettingPhase 4Cranston
A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose WeightPhase 3Cumberland
AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose WeightPhase 3Cumberland
AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose WeightPhase 3Cumberland
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)Phase 3East Greenwich
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASHPhase 3East Greenwich
Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)Phase 3East Greenwich
HP-211 Safety and Proof of Concept Dose Ranging Study in Patients With Type 2 DiabetesPhase 2East Greenwich
OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular EventsPhase 3East Greenwich
A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DMPhase 3East Providence
A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background DapagliflozinPhase 3East Providence
A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive DisorderPhase 3East Providence
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's DiseasePhase 3East Providence
A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEFPhase 3East Providence
ALTO-207 in Adults With Treatment-resistant Depression (TRD)Phase 2East Providence
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)Phase 2/3East Providence
Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia—East Providence
Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid TumorsPhase 1/2East Providence
Stroke and Systemic Embolism Prevention in Adult Participants With Atrial FibrillationPhase 3East Providence
Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast CancerPhase 2East Providence
Testing Delivery Modalities of Team-Based CBT for Pediatric Anxiety in Community Health Settings.N/AEast Providence
PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 DiabetesPhase 4Pawtucket
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)Phase 3Providence
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)Phase 3Providence
A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid TumorsPhase 1/2Providence
A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid TumorsPhase 1/2Providence
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLCPhase 3Providence
A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With CancerPhase 2Providence
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)Phase 3Providence
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)—Providence
A New Clinical Model for the Engagement of Latinx Youth With Suicidal BehaviorN/AProvidence
A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid TumorsPhase 1Providence
A Phase 1 Study of IM-1021 in Participants With Advanced CancerPhase 1Providence
A Phase 2 Study of ACR-368 in Endometrial AdenocarcinomaPhase 2Providence
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid TumorsPhase 1Providence
A Phase I/II Study of VLS-1488 in Subjects With Advanced CancerPhase 1/2Providence
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)Phase 3Providence
A Platform Study in Non-Small Cell Lung Cancer (NSCLC)Phase 1/2Providence
A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)Phase 3Providence
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast CancerPhase 3Providence
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)Phase 2Providence
A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)Phase 3Providence
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)Phase 3Providence
A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant MetastasesPhase 3Providence
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell MalignanciesPhase 1/2Providence
A Study of AZD3470, a PRMT5 Inhibitor, Given as Monotherapy and in Combination in Patients With MTAP Deficient Advanced/Metastatic Solid TumorsPhase 1/2Providence
A Study of Azenosertib (ZN-c3) in Patients With Ovarian CancerPhase 1Providence
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)Phase 3Providence
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine TherapyPhase 3Providence
A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWTPhase 2Providence
A Study of DS-1103a Combination Therapy in Participants With Advanced Solid TumorsPhase 1Providence
A Study of DS-3939a in Participants With Solid TumorsPhase 1/2Providence
A Study of DS5361b in Participants With Advanced Solid TumorsPhase 1Providence
A Study of DS9051b in Participants With Advanced or Metastatic Adrenocortical Carcinoma and Metastatic Castration-resistant Prostate CancerPhase 1Providence
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of RecurrencePhase 3Providence
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung CancerPhase 3Providence
A Study of Lower Radiotherapy Dose to Treat Children With CNS GerminomaPhase 2Providence
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA MutationPhase 3Providence
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab MonotherapyPhase 1/2Providence
A Study of PYX-201 in Advanced Solid TumorsPhase 1Providence
A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic MutationPhase 2/3Providence
A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)Phase 3Providence
A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial CancerPhase 1/2Providence
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple MyelomaPhase 3Providence
A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing LossPhase 3Providence
A Study of Zanzalintinib in Participants With Recurrent or Progressive MeningiomaPhase 2Providence
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric CancerPhase 3Providence
A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCTPhase 2Providence
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic MutationPhase 2/3Providence
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.Phase 2Providence
A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin LymphomasPhase 1/2Providence
A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other TherapiesPhase 2Providence
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF AlterationsPhase 2Providence
A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.Phase 1/2Providence
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)Phase 2Providence
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)Phase 3Providence
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 MutationsPhase 3Providence
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and NivolumabPhase 3Providence
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian CancerN/AProvidence
A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)Phase 3Providence
A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure PatientsPhase 3Providence
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)Phase 3Providence
A Study to Evaluate PEEL-224 in Patients With Advanced Solid TumorsPhase 1Providence
A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic CancerPhase 3Providence
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)Phase 3Providence
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)Phase 3Providence
A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid TumorsPhase 1Providence
A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's DiseasePhase 3Providence
A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate CancerPhase 1/2Providence
A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate CancerPhase 2Providence
A TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF SHR-A1904 IN SUBJECTS WITH ADVANCED SOLID TUMORSPhase 1/2Providence
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian CancerPhase 3Providence
A Trial of Robotic Versus Open Hysterectomy Surgery in Cervix CancerN/AProvidence
A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other TumorsPhase 1/2Providence
AGENT DCB STANCE: Safety and Effectiveness Study of AGENT Drug-Coated Balloon Compared to Standard of Care Percutaneous Coronary Intervention (PCI) Treatment for de Novo Coronary LesionsN/AProvidence
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2Phase 2Providence
Acoustic Cluster Therapy (ACT) With Chemotherapy for the Treatment of Locally Advanced Pancreatic CancerPhase 2Providence
Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell TumorsPhase 3Providence
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast CancerPhase 3Providence
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPERPhase 2Providence
Alzheimer's Tau Platform: Master ProtocolPhase 2Providence
Anticoagulation in ICH Survivors for Stroke Prevention and RecoveryPhase 3Providence
Assessing Symptom and Mood Dynamics in Pain Using the Smartphone Application SOMA—Providence
Augmented Reality-Cardiopulmonary Resuscitation Support for Pediatric ResuscitationN/AProvidence
Basal Cell Carcinoma Chemoprevention TrialPhase 3Providence
Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of CarePhase 3Providence
Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain MetsPhase 3Providence
BrUOG 397: NEO Rad (LOW): Neoadjuvant Low Dose Stereotactic Body Radiotherapy, Ipilimumab and NivolumabPhase 2Providence
Brain Connectivity in DepressionN/AProvidence
Breathe Easier With Tadalafil Therapy for Dyspnea in COPD-PHPhase 2Providence
Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative RhabdomyosarcomaPhase 3Providence
Cognitive Strategies for Weight LossN/AProvidence
Collaborative Care Model for Perinatal Wellness Support Services - Population-Level Equity-Centered Systems ChangeN/AProvidence
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection—Providence
Collection of Research Data and Samples From Patients Treated With Immunotherapy to Study Its Side Effects—Providence
Colon Adjuvant Chemotherapy Based on Evaluation of Residual DiseasePhase 2/3Providence
Comparing Cooling and/or Compression Approaches of Limbs for Prevention of Chemotherapy-Induced Peripheral NeuropathyPhase 3Providence
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)Phase 2Providence
Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)Phase 2Providence
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)Phase 2Providence
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular LymphomaPhase 3Providence
Comparison of the Outcomes of Single vs Multiple Arterial Grafts in WomenN/AProvidence
Control Systems Engineering for Weight Loss MaintenancePhase 2Providence
DECIDE: A Comparative Effectiveness Trial of Metformin Versus Insulin for the Treatment of Gestational DiabetesPhase 4Providence
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial CancerPhase 3Providence
DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed MedulloblastomaPhase 2Providence
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)Phase 3Providence
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk NeuroblastomaPhase 3Providence
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA ResponsePhase 3Providence
Dominantly Inherited Alzheimer Network (DIAN)—Providence
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)Phase 1Providence
E-Mindfulness Approaches for Living After Breast CancerPhase 3Providence
EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed GlioblastomaPhase 3Providence
EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)—Providence
Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACSPhase 3Providence
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment—Providence
Efficacy and Safety of the CG-100 Intraluminal Bypass DeviceN/AProvidence
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25Phase 3Providence
Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or AstrocytomaPhase 1Providence
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCCPhase 2/3Providence
Fabry Disease Registry & Pregnancy Sub-registry—Providence
Feasibility and Acceptability of a Novel Digital Intervention to Prevent Paternal Postpartum DepressionN/AProvidence
First-in-Human Study of DS-3939a in Participants With Advanced Solid TumorsPhase 1/2Providence
First-in-Human Study to Evaluate AZD8359 STEAP2 TCE in Participants With Prostate CancerPhase 1/2Providence
Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous PolypsN/AProvidence
Genomically Profiling, Collecting, Archiving and Distributing Hematologic Malignancy Specimens—Providence
Groningen International Study on Sentinel Nodes in Vulvar Cancer-IIIPhase 2Providence
Head and Neck Cancer Study Project in the Geriatric PopulationPhase 3Providence
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic CancersPhase 1/2Providence
INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)Phase 2Providence
IVUS CHIP UPP Registry—Providence
Identifying Findings on Brain Scans That Could Help Make Better Predictions About Brain Cancer Progression, The GABLE TrialPhase 2Providence
Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors—Providence
Impact of Bromocriptine on Clinical Outcomes for Peripartum CardiomyopathyPhase 4Providence
Impact of Sentinel Lymph Node Mapping on Patient Reported Lower Extremity Limb Dysfunction in Stage I Endometrial CancerPhase 3Providence
Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical CancerPhase 3Providence
Injection of Botulinum Toxin for Thumb Carpometacarpal ArthritisPhase 3Providence
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic LeukemiaPhase 3Providence
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLyPhase 3Providence
Intensive Glycemic Targets in Overweight and Obese Women With Gestational DiabetesN/AProvidence
Intraoperative Music Therapy in TAVR PatientsN/AProvidence
JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung CancerPhase 3Providence
L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AMLPhase 2/3Providence
Lifestyle Interventions to Prevent Diabetes in U.S. Home Visiting ProgramsN/AProvidence
Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies—Providence
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung CancerPhase 2/3Providence
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)Phase 2Providence
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)Phase 3Providence
Microrandomized Trial to Optimize Use of Burden-reducing Self-monitoring Approaches in Behavioral Obesity TreatmentN/AProvidence
Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone LymphomaPhase 2Providence
Multi-Institutional Registry for Malignant Peripheral Nerve Sheath Tumors—Providence
Observational Study of Pediatric Rheumatic Diseases: The CARRA Registry—Providence
Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical CancerPhase 4Providence
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)Phase 3Providence
Optimizing an Online Behavioral Weight Loss Intervention and Novel Culturally Tailored Components for Sexual Minority WomenN/AProvidence
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus PembrolizumabPhase 3Providence
Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)—Providence
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7Phase 2/3Providence
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid TumorsPhase 1/2Providence
Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal CancerPhase 3Providence
Pilot Trial of Supplemental Vitamin A and NicotinamideEarly 1Providence
Prevail Global StudyN/AProvidence
Preventing Dato-DXd Associated Stomatitis With Dexamethasone Mouthwash, TROPION-DMPhase 2Providence
Primary Tumor Research and Outcomes Network—Providence
Project: Every Child for Younger Patients With Cancer—Providence
Quality of End-of-Life Care for Children With Cancer—Providence
Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)—Providence
Remote Approaches for Optimizing Weight Loss (Elevate Weight Loss Trial)N/AProvidence
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)Phase 1/2Providence
SMART to Optimize an Intervention to Maintain Health Improvements After Cardiac RehabilitationN/AProvidence
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry—Providence
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease StudiesPhase 3Providence
Self Neuro-modulation Therapy for Major Depressive Disorder (MDD) With AnhedoniaN/AProvidence
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus TrastuzumabPhase 3Providence
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast CancerPhase 3Providence
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid TumorsPhase 1/2Providence
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2Phase 3Providence
Staged Complete Revascularization for Coronary Artery Disease vs Medical Management Alone in Patients With AS Undergoing Transcatheter Aortic Valve ReplacementN/AProvidence
Study Comparing Acceptance and Commitment Therapy to Supportive Diabetes Counseling and a Waitlist Control for Eating Disorders in Type 1 DiabetesN/AProvidence
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic TumorsPhase 1Providence
Study of ACR-2316 in Specific Advanced Solid TumorsPhase 1/2Providence
Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate CancerPhase 1/2Providence
Study of AZD4956 as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homologous Recombination Deficient Solid TumoursPhase 1/2Providence
Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell MalignanciesPhase 1/2Providence
Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial CarcinomaPhase 2/3Providence
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)Phase 1Providence
Study of Lunresertib Alone or in Combination With RP-3500 or Zedoresertib (Debio 0123) in Patients With Advanced Solid TumorsPhase 1Providence
Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 MutationPhase 3Providence
Study of SGR-1505 in Mature B-Cell NeoplasmsPhase 1Providence
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)Phase 3Providence
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid TumorsPhase 1Providence
Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)Phase 3Providence
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400Phase 1Providence
Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney FunctionPhase 3Providence
Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal SarcomaPhase 3Providence
TIDES 2.0: Prevalence and Longitudinal Course of Depression, Anxiety, and Behavior Problems in Children With Cystic Fibrosis Under 12 Years of Age—Providence
TLR9 Immunotherapy for Peritoneal CarcinomatosisPhase 1Providence
Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating AgentsPhase 2Providence
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening TrialPhase 2Providence
Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell LymphomaPhase 3Providence
Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial CancerPhase 1Providence
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic CancerPhase 3Providence
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)Phase 2Providence
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial CarcinomaPhase 2Providence
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian CancerPhase 3Providence
Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low TrialPhase 3Providence
Testing for Safety and Colorectal Cancer Preventive Effects of ONC201Phase 1Providence
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)Phase 3Providence
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLLPhase 3Providence
Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell LymphomaPhase 2Providence
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])Phase 3Providence
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial CancerPhase 3Providence
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged LeukemiaPhase 2Providence
Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)Phase 2Providence
The Ailliance Post-Market Clinical StudyN/AProvidence
The Dream Team: Testing Implementation of a Sleep Intervention for Perinatal Women Delivered by Direct Care WorkersN/AProvidence
The Effects of a Low Glycemic Load Diet on Dysglycemia and Body Composition in Adults With Cystic Fibrosis-Related DiabetesN/AProvidence
The Fourth Left Atrial Appendage Occlusion StudyN/AProvidence
The Mindful Smartphone Use StudyN/AProvidence
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group StudyPhase 1/2Providence
The Puerto Rico Asthma Integrated Response Program ("PR-AIR")N/AProvidence
The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial FibrillationPhase 3Providence
Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With OsteosarcomaPhase 3Providence
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial CancerPhase 2Providence
Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With CancerPhase 3Providence
Type 1 Diabetes Adolescents for Healthier Lifestyles StudyN/AProvidence
Use of CA125 and Complementary Biomarkers for the Early Detection of Ovarian Cancer in Low Risk WomenN/AProvidence
Using Microbiome to Predict Durvalumab Toxicity in Post- Concurrent Chemoradiation Therapy (CCRT) NSCLC Patients—Providence
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)Phase 2Providence
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive MeningiomasPhase 2Providence
Weight Management Intervention in College: A PilotN/AProvidence
Y-90, Capecitabine, and Atezolizumab for Oligometastatic CRCPhase 2Providence
FX Shoulder Prospective Clinical Study—Wakefield
Screening Study for KIT D816V Mutated Mast Cell Disease in Select Populations—Warwick
ATEMPT 2.0: Adjuvant T-DM1 vs THPhase 2Westerly
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE TrialPhase 2/3Westerly
Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at DiagnosisPhase 3Westerly
Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene MutationPhase 2Westerly
Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT TrialPhase 2Westerly
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable TreatmentPhase 3Westerly
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)Phase 2Westerly
Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers—Westerly
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering MyelomaPhase 3Westerly
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung CancerPhase 3Westerly
QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer—Westerly
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone SurgeryPhase 2Westerly
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast CancerN/AWesterly
Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid CancerPhase 3Westerly
Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal CavityPhase 2/3Westerly
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney CancerPhase 3Westerly
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN StudyPhase 2/3Westerly
Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine TumorsPhase 2Westerly
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE TrialPhase 3Westerly
The CDK4/6 Inhibitor Dosing Knowledge (CDK) StudyPhase 3Westerly

Frequently Asked Questions

How many clinical trials are recruiting in Rhode Island?

There are currently 274 actively recruiting clinical trials in Rhode Island across 9 cities.

Which cities in Rhode Island have the most clinical trials?

The top cities are Providence (230 trials), Westerly (32 trials), East Providence (12 trials).

What conditions are being studied in Rhode Island?

Researchers in Rhode Island are studying Alzheimer's Disease, Anxiety, Arthritis, Asthma, Breast Cancer, and 10 more conditions.

What trial phases are available in Rhode Island?

Available phases include Phase 3 (36%), Phase 2 (18%), NA (12%).

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.